Meanwhile, we elucidated a novel cross-regulation between MyD88 and STAT3 or Smad3, thus reaffirming the plausibility of MyD88 as a potential therapeutic target for renal fibrosis. This evidence concerns the gene STAT3 and renal fibrosis.